The protective advantage of hybrid immunity likely arises from a combination of higher numbers of SARS-CoV-2-specific MBCs, elevated neutralizing antibody titers, and an infection-induced cytokine profile of IFN-γ and IL-10 in CD4+ T cells. This evidence concerns the gene CD4 and infection.